Business
Fangzhou Launches Otsuka's Third-Generation Leukemia Drug Ponatinib on its Platform
Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced the availability of Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor (TKI) Iclusig® (ponatinib) through its online platform, providing expanded treatment options for patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Iclusig®, approved in China in September 2024, has demonstrated particular efficacy a
About this update from Fangzhou Inc.
[{"type":"text","content":"GUANGZHOU, China, May 5, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced the availability of Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor (TKI) Iclusig® (ponatinib) through its online platform, providing expanded treatment options for patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Iclusig®, approved in China in September 2024, has demonstrated particular efficacy against T315I-mutated BCR::ABL1 disease that is resistant to first and second generation TKIs, with the OPTIC trial showing a four-year survival rate of 88% among certain patient cohorts.","length":766,"tagName":"p"},{"type":"image","alt":"Fangzhou Inc. (PRNewsfoto/Fangzhou Inc.)","displaySize":"","headline":null,"caption":"Fangzhou Inc. (PRNewsfoto/Fangzhou Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":127,"url":"https://media.zenfs.com/en/prnewswire.com/ec3b6ecc368092a3d079d531670f2342"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UzhMEweRObfFg12_yi_6IQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIyNDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/ec3b6ecc368092a3d079d531670f2342","width":400,"height":127}},"href":"https://mma.prnewswire.com/media/2544392/Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, commented, "As a platform focused on patient-centered healthcare, we are committed to bringing innovative treatments such as Iclusig® to Chinese patients through our digital healthcare ecosystem."","length":263,"tagName":"p"},{"type":"text","content":"Deep Collaboration with Pharmaceutical Companies","length":48,"tagName":"p"},{"type":"text","content":"Fangzhou has developed strong partnerships with leading domestic and multinational pharmaceutical companies, along with a comprehensive drug supply chain spanning multiple therapeutic areas including oncology, liver disease, and cardiovascular, and now offering over 210,000 drug SKUs to meet the diverse needs patient chronic disease patients. By harnessing AI, big data, and cloud computing technologies, Fangzhou is focused on continually enhancing its health management se...